Business Wire

TX-ASCEND-PERFORMANCE

Share
Ascend Launches Acteev Protect™ Antimicrobial Technology

Ascend Performance Materials has introduced Acteev Protect™, a breakthrough technology specially formulated to guard against the growth of mildew, fungi and other microbes to keep textiles and nonwoven fabrics fresher for longer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200615005732/en/

The technology is a leap forward in protection for face masks, apparel, upholstery, air filters and more, said Lu Zhang, Ph.D., Ascend’s vice president leading the Acteev launch. “Bacteria, mildew and other microbes growing on fabrics and filters cause the item to break down, discolor and give off unpleasant smells,” she said. “Acteev Protect guards against that microbial growth, keeping the articles clean.”

The technology has been in development for several years, but with the recent shortage of articles resistant to microbial growth, Ascend accelerated the product launch by partnering with independent labs for testing and reallocating resources to scale up production. “The current global scarcity of microbe-resistant materials is not going to end unless manufacturers are able to obtain the right media,” Dr. Zhang said. “We saw a way we could quickly meet those urgent needs with this innovative technology.”

Acteev Protect combines zinc ion technology with polyamide-based woven, nonwoven and knit fabrics. The active zinc ions are embedded into the polymer matrix, providing a long-lasting solution that does not wash away, unlike topical finishes or coatings. The polyamide fabrics are durable yet soft to the skin, and the nonwoven filtration media – available as nanofibers, meltblown and spunbond – efficiently keep out unwanted particles.

The embedded zinc in its ionic form is a powerful inhibitor of bacterial growth, said Vikram Gopal, Ph.D., Ascend’s senior vice president of technology. “Zinc is an essential element needed for bacterial growth, so bacteria readily allows it inside the cell body. But the zinc ion outcompetes other essential elements such as manganese and magnesium and chokes their ingestion channels,” he said. “Without those minerals, the microbes can’t grow or reproduce.”

Other products use silver as an antimicrobial, Dr. Gopal said, but that metal comes with unwanted environmental consequences. “Silver is typically used as a finish or a coating,” he said. “That process is water-intensive, and the excess silver has to be disposed of, eventually ending up in our waterways.”

Zinc, however, is labeled Generally Regarded as Safe by the U.S. Food and Drug Administration.

Additionally, the fabrics feature all the benefits of premium polyamides, which offer more comfort than polypropylene in single-use masks and allows knits and wovens to be dyed, printed on and laundered.

Polyamide 66 wovens and knits have considerable advantages over other types of nylons in garments and other textile applications, said Harrie Schoots, president-elect of the American Association of Textile Chemists and Colorists and a senior business leader of Ascend’s textile business.

“This material resists abrasion and doesn’t pill or shed microfibers. It has a soft hand and excellent drape, and it can be dyed solid or bright colors,” Schoots said. “Uniforms or activewear made with Acteev Protect will be durable and comfortable and can be designed to match current color trends.”

Additionally, these features will last the lifetime of the garment. “Because the zinc ions are embedded during the polymerization process, knit and woven articles made with Acteev Protect stand up to 50 washes or more,” Schoots said.

Ascend is the world’s largest fully integrated producer of polyamide 66 resins and also manufactures fibers and chemicals. Acteev Protect is the company’s first product offering available in ready-to-use fabric form factors. The company plans to extend the line in the coming months to include polyamide 66 fabrics for medical applications and engineered plastics for high-touch surfaces.

For more information, to request a sample or to see performance data, please visit ascendmaterials.com/acteevprotect .

Acteev Protect does not protect users or others against disease-causing bacteria.

About Ascend Performance Materials

Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has nine global locations, including five fully-integrated manufacturing facilities located in the southeastern United States and an engineering plastics compounding facility in Europe, all dedicated to the innovation and safe production. With three of the world’s largest chemical processing facilities, Ascend’s materials form the building blocks for products used in everyday applications from apparel to airbags, cable ties to circuit boards and carpets to car parts. Ascend’s 2,600-person global workforce is committed to making a difference in the communities we serve and leading the development of material solutions that inspire everyone, everywhere, every day.

Together, we’re making a difference.
Together, we’re inspiring everyday.

More information about Ascend can be found at www.ascendmaterials.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye